Core Viewpoint - The report highlights the financial performance and operational challenges faced by Shanghai Rendu Biotechnology Co., Ltd., particularly in its main business segments of RNA molecular testing reagents, instruments, and testing services, with significant fluctuations in revenue and profit margins across different product lines. Group 1: Main Business Performance - The company's main business includes RNA molecular testing reagents, instruments, and testing services, with overall revenue growth of 9.94%. Instrument revenue reached 8.71 million yuan, a year-on-year increase of 19.88%, while testing services revenue was 6.48 million yuan, down 32.83% [1][2][8]. - The gross profit margin for reagents remained stable compared to the previous year, while the gross margins for instruments and testing services decreased significantly, with margins at 0.1% and -3.61%, respectively, reflecting a decline of 16.56 percentage points and 74.76 percentage points [1][6][8]. Group 2: Customer Analysis - The top five customers for reagents generated a total revenue of 28.84 million yuan, with significant changes in procurement volumes due to market dynamics. For instance, Jiangxi Yingge Medical Equipment Co., Ltd. saw a notable increase in reagent procurement following hospital access approvals [2][4]. - The top five customers for instruments accounted for 6.04 million yuan in revenue, with a shift towards new customers, indicating a change in procurement patterns [4][5]. Group 3: Sales and Revenue Breakdown - In 2024, the reagent business generated 111.13 million yuan, accounting for 68.35% of total revenue, with a year-on-year growth of 6.85%. The blood-related series saw significant revenue growth due to new product launches [6][8]. - The instrument sales included 836.97 million yuan from the AutoSAT system, representing a 96.12% increase, while other instruments saw a decline in sales [6][8]. Group 4: Financial Challenges - The company faced a 50.85% decrease in testing service revenue due to reduced public health testing demand, which also led to a significant drop in gross margins for this segment [8][10]. - The accounts receivable balance stood at 72.64 million yuan, with a significant increase in bad debt provisions amounting to 20.73 million yuan, reflecting challenges in customer payment capabilities [10][11]. Group 5: Expense Management - Sales expenses decreased by 0.97% to 89.86 million yuan, with a notable reduction in employee compensation contributing to this decline. The sales expense ratio remains high compared to industry peers due to the company's smaller revenue scale and the need for increased market promotion [16][17][18]. - The company reported a significant increase in accrued expenses, particularly for business service fees, reflecting ongoing efforts to manage operational costs effectively [19][20]. Group 6: Fund Utilization - The company raised 652.76 million yuan in its IPO, with 252.83 million yuan invested by the end of 2024, indicating a progress rate of 36.09%. The funds are primarily allocated to R&D projects and marketing network development [20][21].

Core Viewpoint - Shanghai Rendu Biotechnology Co., Ltd. received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, prompting a detailed response about its business performance and financials [1]. Business Overview - The company's main business includes RNA molecular testing reagents, instruments, and testing services, with a revenue growth of 9.94% [1]. - Instrument business revenue reached 8.71 million yuan, a year-on-year increase of 19.88%, while testing services revenue was 6.48 million yuan, a decline of 32.83% [1]. Customer Analysis - The top five customers for reagents generated a total sales revenue of 28.84 million yuan, with significant changes in procurement volumes due to market dynamics [1]. - The top five customers for instruments contributed 6.04 million yuan, with a notable shift towards new clients [3][4]. Revenue Breakdown - Reagent sales accounted for 68.35% of total revenue, with significant growth in blood-related series products due to new product launches [4]. - Instrument sales included 46 units of the AutoSAT system, with a 25.26% increase in revenue [5]. Profit Margin Analysis - The gross margin for reagent business remained stable, while the gross margin for instruments and testing services decreased significantly, attributed to market competition and pricing strategies [5][6]. - The overall gross margin for testing services was 79.49%, reflecting a slight decline from the previous year [6]. Bad Debt Provision - The company reported accounts receivable of 72.64 million yuan, with a significant increase in bad debt provision amounting to 20.73 million yuan, reflecting a cautious approach to credit risk management [7][8]. - The increase in bad debt was primarily due to the nature of clients acquired during the public health crisis, which were deemed to have higher credit risk [10][11]. Expense Management - Sales expenses decreased by 19% year-on-year, with a notable reduction in employee compensation and a strategic focus on cost control [14][15]. - The sales expense ratio remains high compared to industry peers, justified by the company's smaller revenue scale and the need for increased market promotion efforts [16][17]. Fund Utilization - The company raised 652.76 million yuan in its initial public offering, with 36.09% of the funds utilized by the end of 2024, primarily for R&D and marketing network projects [21].